![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Active Filter(s):
Details:
ISLA-101, has been granted by the United States Patent & Trademark Office. ISLA-101 is a drug with a very well-known safety profile, being repurposed for mosquito borne viruses.
Lead Product(s): ISLA-101
Therapeutic Area: Infections and Infectious Diseases Product Name: ISLA-101
Highest Development Status: Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: State University of New York
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2021